Various laser treatments are used to treat hyperpigmented lesions such as solar lentigo and chloasma. However, they often leave unwanted postinflammatory hyperpigmentation (PIH) especially in dark-skinned individuals. A topical gel of brimonidine is a highly selective α-2 adrenergic agonist approved for the treatment of rosacea due to its potent vasoconstrictive activity in cutaneous blood vessels. Two middle-aged man with Fitzpatrick skin type IV underwent Q-switched laser treatment in our clinic to remove solar lentigines from their face. Prior to and after laser treatment, topical brimonidine gel was applied to one of the lentigines. Brimonidine-applied lesions showed more significant improvement leaving less PIH than non-applied lesions. Herein, we suggest topical application of brimonidine could reduce PIH after Q-switched laser treatment of lentigine in a dark-skinned patient.